Regeneron Pharmaceuticals has agreed to purchase genetic testing company 23andMe for $256 million through a bankruptcy auction, marking a significant decline from 23andMe's peak valuation of $6 billion when it went public in 2021.
Regeneron Acquires 23andMe for $256 Million Amid Privacy Concerns